Clearmind Medicine Announces Shareholders Meeting Results Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on...

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...

Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute U.S. Patent and Trademark Office extends protection of Clearmind’s  proprietary MEAI and expands its potential market  Tel Aviv, Israel / Vancouver, Canada, Dec. 21, 2022 (GLOBE NEWSWIRE) --...